Julie Di Paolo
Senior Director, Immunology Therapeutic Area Lead Johnson & Johnson
Julie Di Paolo, PhD, is Senior Director and Immunology Scientific Innovation Lead at the Johnson & Johnson Boston Innovation Center, where she focuses on identifying and advancing external innovation and partnerships in immunology. Prior to joining Johnson & Johnson in 2022, Julie spent over a decade at Gilead Sciences, where she served as Executive Director and led research in inflammation biology, advancing programs targeting complex immune-mediated diseases. Earlier in her career, she held a series of scientific leadership roles at CGI Pharmaceuticals, building deep expertise in molecular biology and drug discovery. Julie began her scientific training with a PhD in Biochemical Pharmacology from Brown University followed by postdoctoral research at Yale School of Medicine.
Seminars
- Which stage of development is most appealing in Immunology?
- What are the starting points, from a data package perspective, when it comes to assessing engagers or in vivo CAR-T?
- When evaluating an early-stage what level of data—whether safety, biomarkers, or efficacy—provides you with conviction that the program has true drug potential?
- Which diseases do you think are most promising for B-cell targeted therapies?
